NCT06778031View on ClinicalTrials.gov

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

September 30, 2028

Conditions
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811.

DRUG

SHR-1316

SHR-1316.

DRUG

SHR-8068

SHR-8068.

Trial Locations (2)

150000

RECRUITING

Affiliated Cancer Hospital of Harbin Medical University, Harbin

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY